Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)
China · Delayed Price · Currency is CNY 39.38
-0.67 (-1.67%)
Aug 14, 2026, 3:00 PM CST
SHA:600211 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,535 | 13,715 | 11,906 | 12,099 | 8,906 | 12,982 | |
Market Cap Growth | -17.95% | 15.19% | -1.59% | 35.86% | -31.40% | -22.18% |
Enterprise Value | 10,236 | 11,801 | 9,880 | 10,369 | 7,662 | 12,467 |
Last Close Price | 39.38 | 41.64 | 34.53 | 33.60 | 23.86 | 34.47 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.89 | 14.62 | 11.33 | 15.11 | 24.08 | 62.13 |
Forward PE | - | 10.16 | 10.20 | 9.13 | 26.48 | 26.48 |
PS Ratio | 4.34 | 4.60 | 4.24 | 3.86 | 3.49 | 6.07 |
PB Ratio | 2.97 | 3.32 | 3.01 | 3.59 | 2.94 | 4.91 |
P/TBV Ratio | 3.52 | 4.02 | 3.20 | 3.86 | 3.44 | 5.88 |
P/FCF Ratio | 14.41 | 13.87 | 12.44 | 11.62 | 12.11 | - |
P/OCF Ratio | 14.19 | 13.65 | 11.97 | 11.38 | 10.64 | 35.42 |
PEG Ratio | - | 1.05 | 1.05 | 1.05 | 1.05 | 1.05 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.55 | 3.96 | 3.52 | 3.31 | 3.00 | 5.83 |
EV/EBITDA Ratio | 9.58 | 11.78 | 10.20 | 9.37 | 10.12 | 19.06 |
EV/EBIT Ratio | 10.43 | 12.76 | 11.06 | 9.98 | 11.13 | 21.77 |
EV/FCF Ratio | 11.76 | 11.93 | 10.32 | 9.95 | 10.42 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.27 | 0.20 | 0.07 | 0.15 | 0.16 | 0.20 |
Debt / EBITDA Ratio | 1.06 | 0.84 | 0.28 | 0.45 | 0.64 | 0.82 |
Debt / FCF Ratio | 1.30 | 0.85 | 0.29 | 0.48 | 0.66 | - |
Net Debt / Equity Ratio | -0.62 | -0.63 | -0.59 | -0.56 | -0.48 | -0.29 |
Net Debt / EBITDA Ratio | -2.44 | -2.60 | -2.43 | -1.69 | -1.91 | -1.17 |
Net Debt / FCF Ratio | -3.00 | -2.64 | -2.46 | -1.80 | -1.96 | 12.93 |
Asset Turnover | 0.48 | 0.54 | 0.60 | 0.72 | 0.65 | 0.63 |
Inventory Turnover | 1.11 | 1.09 | 1.32 | 1.50 | 1.73 | 2.17 |
Quick Ratio | 2.72 | 2.67 | 4.40 | 2.74 | 2.51 | 1.76 |
Current Ratio | 2.88 | 2.83 | 4.66 | 2.87 | 2.64 | 1.97 |
Return on Equity (ROE) | 21.79% | 22.67% | 28.86% | 25.30% | 13.23% | 8.14% |
Return on Assets (ROA) | 10.13% | 10.49% | 11.96% | 14.95% | 10.89% | 10.61% |
Return on Invested Capital (ROIC) | 56.18% | 52.08% | 52.87% | 60.70% | 32.15% | 25.90% |
Return on Capital Employed (ROCE) | 20.70% | 20.00% | 22.40% | 30.50% | 22.40% | 21.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.81% | 6.84% | 8.83% | 6.62% | 4.15% | 1.61% |
FCF Yield | 6.94% | 7.21% | 8.04% | 8.61% | 8.26% | -0.46% |
Dividend Yield | 4.46% | 4.22% | 5.67% | 4.44% | 2.40% | 0.75% |
Payout Ratio | 58.95% | 65.41% | 47.95% | 61.74% | 26.55% | 63.41% |
Buyback Yield / Dilution | 0.60% | 0.05% | 0.14% | -0.09% | 0.21% | -0.53% |
Total Shareholder Return | 5.06% | 4.27% | 5.81% | 4.35% | 2.61% | 0.22% |